Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype (NIMBLE)
Summary
The purpose of this clinical research study is to look at whether the investigational study drug, GSK3511294, works and how safe it is with severe asthma with an eosinophilic phenotype.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 80
Inclusion criteria:
You might be eligible if:
1) 18 to 80 years of age.
2) you have severe asthma with an eosinophilic phenotype.
Exclusion criteria:
You might not be eligible if:
1) you do not have severe asthma with an eosinophilic phenotype
2) you are under the age of 18
3) you are pregnant
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
If you would like to learn more about how you can get involved with this trial, please contact our study coordinator, Curtis, at 403-220-2123
Principal investigator:
Richard Leigh
Clinical trial:
Yes
REB-ID:
REB22-1811